Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol propionate ophthalmic suspension 0.05% (APP13007) across 11 countries, including India. It is used to treat post-op inflammation and pain following ocular surgery.
